Literature DB >> 16815849

Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.

Laurie S Spofford1, Ethan V Abel, Karen Boisvert-Adamo, Andrew E Aplin.   

Abstract

D-type cyclins regulate G1 cell cycle progression by enhancing the activities of cyclin-dependent kinases (CDKs), and their expression is frequently altered in malignant cells. We and others have previously shown that cyclin D1 is up-regulated in melanoma cells through adhesion-independent MEK-ERK1/2 signaling initiated by mutant B-RAF. Here, we describe the regulation and role of cyclin D3 in human melanoma cells. Cyclin D3 expression was enhanced in a cell panel of human melanoma cell lines compared with melanocytes and was regulated by fibronectin-mediated phosphatidylinositol 3-kinase/Akt signaling but not MEK activity. RNA interference experiments demonstrated that cyclin D3 contributed to G1-S cell cycle progression and proliferation in melanoma cells. Overexpression of cyclin D1 did not recover the effects of cyclin D3 knockdown. Finally, immunoprecipitation studies showed that CDK6 is a major binding partner for cyclin D3, whereas CDK4 preferentially associated with cyclin D1. Together, these findings demonstrate that cyclin D3 is an important regulator of melanoma G1-S cell cycle progression and that D-type cyclins are differentially regulated in melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815849      PMCID: PMC4266577          DOI: 10.1074/jbc.M600197200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects.

Authors:  G De Vita; M T Berlingieri; R Visconti; M D Castellone; G Viglietto; G Baldassarre; M Zannini; A Bellacosa; P N Tsichlis; A Fusco; M Santoro
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

2.  Tumor suppression without differentiation or apoptosis by antisense cyclin D1 gene transfer in K1735 melanoma involves induction of p53, p21WAF1 and superoxide dismutases.

Authors:  M Rieber; M S Rieber
Journal:  Cell Death Differ       Date:  1999-12       Impact factor: 15.828

3.  Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.

Authors:  Kavita V Bhatt; Laurie S Spofford; Gazelle Aram; Meghan McMullen; Kevin Pumiglia; Andrew E Aplin
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

4.  PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.

Authors:  X Zhu; C H Kwon; P W Schlosshauer; L H Ellenson; S J Baker
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

5.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

6.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.

Authors:  Jingsong Zhang; Siwen Hu; Deborah E Schofield; Poul H B Sorensen; Timothy J Triche
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

9.  Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

Authors:  K J Sweeney; A Swarbrick; R L Sutherland; E A Musgrove
Journal:  Oncogene       Date:  1998-06-04       Impact factor: 9.867

10.  Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

View more
  19 in total

1.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 2.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

3.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

4.  In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Authors:  Kevin J Basile; Ethan V Abel; Neda Dadpey; Edward J Hartsough; Paolo Fortina; Andrew E Aplin
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 5.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

6.  Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Marco De Dominici; Patrizia Porazzi; Angela Rachele Soliera; Samanta A Mariani; Sankar Addya; Paolo Fortina; Luke F Peterson; Orietta Spinelli; Alessandro Rambaldi; Giovanni Martinelli; Anna Ferrari; Ilaria Iacobucci; Bruno Calabretta
Journal:  Cancer Res       Date:  2017-12-12       Impact factor: 12.701

7.  Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

Authors:  Ethan V Abel; Kevin J Basile; Curtis H Kugel; Agnieszka K Witkiewicz; Kaitlyn Le; Ravi K Amaravadi; Giorgos C Karakousis; Xiaowei Xu; Wei Xu; Lynn M Schuchter; Jason B Lee; Adam Ertel; Paolo Fortina; Andrew E Aplin
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

8.  Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.

Authors:  Nai-Ying Yang; Carlos Fernandez; Melanie Richter; Zhan Xiao; Fatima Valencia; David A Tice; Elena B Pasquale
Journal:  Cell Signal       Date:  2010-09-15       Impact factor: 4.315

9.  Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  Cyclin D1 and D3 expression in melanocytic skin lesions.

Authors:  Ana Alekseenko; Anna Wojas-Pelc; Grzegorz J Lis; Alicja Furgał-Borzych; Grzegorz Surówka; Jan A Litwin
Journal:  Arch Dermatol Res       Date:  2010-05-23       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.